These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 33655428)

  • 21. Tumor Volume on Biopsy of Low Risk Prostate Cancer Managed with Active Surveillance.
    Tosoian JJ; Mamawala M; Patel HD; Alam R; Epstein JI; Ross AE; Carter HB
    J Urol; 2018 Apr; 199(4):954-960. PubMed ID: 29074222
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Active surveillance in males with low- to intermediate-risk localized prostate cancer: A modern prospective cohort study.
    Rakauskas A; Tawadros T; Lucca I; Herrera F; Bourhis J; Burruni R; Gomes MN; Codeluppi C; Jolliet L; La Rosa S; Meuwly JY; Jichlinski P; Berthold D; Valerio M
    Investig Clin Urol; 2021 Jul; 62(4):416-422. PubMed ID: 34190436
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systematic Review and Meta-analysis of Factors Determining Change to Radical Treatment in Active Surveillance for Localized Prostate Cancer.
    Simpkin AJ; Tilling K; Martin RM; Lane JA; Hamdy FC; Holmberg L; Neal DE; Metcalfe C; Donovan JL
    Eur Urol; 2015 Jun; 67(6):993-1005. PubMed ID: 25616709
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Active surveillance for prostate cancer: past, present and future.
    Singer EA; Kaushal A; Turkbey B; Couvillon A; Pinto PA; Parnes HL
    Curr Opin Oncol; 2012 May; 24(3):243-50. PubMed ID: 22450149
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Understanding the Performance of Active Surveillance Selection Criteria in Diverse Urology Practices.
    Hawken SR; Womble PR; Herrel LA; Ye Z; Linsell SM; Hurley PM; Montie JE; Miller DC;
    J Urol; 2015 Nov; 194(5):1253-7. PubMed ID: 25981805
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Active Surveillance Versus Watchful Waiting for Localized Prostate Cancer: A Model to Inform Decisions.
    Loeb S; Zhou Q; Siebert U; Rochau U; Jahn B; Mühlberger N; Carter HB; Lepor H; Braithwaite RS
    Eur Urol; 2017 Dec; 72(6):899-907. PubMed ID: 28844371
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advances in the selection of patients with prostate cancer for active surveillance.
    Liu JL; Patel HD; Haney NM; Epstein JI; Partin AW
    Nat Rev Urol; 2021 Apr; 18(4):197-208. PubMed ID: 33623103
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of MRI in active surveillance for men with localized prostate cancer.
    Recabal P; Ehdaie B
    Curr Opin Urol; 2015 Nov; 25(6):504-9. PubMed ID: 26372037
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Radical prostatectomy versus deferred treatment for localised prostate cancer.
    Vernooij RW; Lancee M; Cleves A; Dahm P; Bangma CH; Aben KK
    Cochrane Database Syst Rev; 2020 Jun; 6(6):CD006590. PubMed ID: 32495338
    [TBL] [Abstract][Full Text] [Related]  

  • 30. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.
    Mottet N; Bellmunt J; Bolla M; Briers E; Cumberbatch MG; De Santis M; Fossati N; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; Matveev VB; Moldovan PC; van den Bergh RCN; Van den Broeck T; van der Poel HG; van der Kwast TH; Rouvière O; Schoots IG; Wiegel T; Cornford P
    Eur Urol; 2017 Apr; 71(4):618-629. PubMed ID: 27568654
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Population-Based Assessment of Determining Treatments for Prostate Cancer.
    Chamie K; Williams SB; Hu JC
    JAMA Oncol; 2015 Apr; 1(1):60-7. PubMed ID: 26182305
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Active surveillance for favorable risk prostate cancer: rationale, results, and vis a vis focal therapy role.
    Klotz L
    Minerva Urol Nefrol; 2011 Jun; 63(2):145-53. PubMed ID: 21623332
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes.
    Cooperberg MR; Brooks JD; Faino AV; Newcomb LF; Kearns JT; Carroll PR; Dash A; Etzioni R; Fabrizio MD; Gleave ME; Morgan TM; Nelson PS; Thompson IM; Wagner AA; Lin DW; Zheng Y
    Eur Urol; 2018 Aug; 74(2):211-217. PubMed ID: 29433975
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Decade of Active Surveillance in the PRIAS Study: An Update and Evaluation of the Criteria Used to Recommend a Switch to Active Treatment.
    Bokhorst LP; Valdagni R; Rannikko A; Kakehi Y; Pickles T; Bangma CH; Roobol MJ;
    Eur Urol; 2016 Dec; 70(6):954-960. PubMed ID: 27329565
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation and Active Treatment versus Active Surveillance of Localized Prostate Cancer in Renal Transplant Patients in the Era of Low and Very Low Risk Prostate Cancer.
    Aminsharifi A; Simon R; Polascik TJ; Robertson CN; Sudan DL; Collins BH; Moul JW
    J Urol; 2019 Sep; 202(3):469-474. PubMed ID: 30835631
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Update and optimization of active surveillance in prostate cancer in 2021.
    Rubio-Briones J; Pastor Navarro B; Esteban Escaño LM; Borque Fernando A
    Actas Urol Esp (Engl Ed); 2021; 45(1):1-7. PubMed ID: 33070989
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Compliance Rates with the Prostate Cancer Research International Active Surveillance (PRIAS) Protocol and Disease Reclassification in Noncompliers.
    Bokhorst LP; Alberts AR; Rannikko A; Valdagni R; Pickles T; Kakehi Y; Bangma CH; Roobol MJ;
    Eur Urol; 2015 Nov; 68(5):814-21. PubMed ID: 26138043
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selecting men diagnosed with prostate cancer for active surveillance using a risk calculator: a prospective impact study.
    van Vugt HA; Roobol MJ; van der Poel HG; van Muilekom EH; Busstra M; Kil P; Oomens EH; Leliveld A; Bangma CH; Korfage I; Steyerberg EW
    BJU Int; 2012 Jul; 110(2):180-7. PubMed ID: 22112199
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Criticisms to patient selection in active surveillance in prostate cancer].
    Gomez Veiga F; Portela Pereira P; Vazquez-Martul Pazos D; Pertega Diaz S; Martinez Breijo S; Mendez Diaz C; Rodríguez E
    Arch Esp Urol; 2014 Jun; 67(5):495-508. PubMed ID: 24914849
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT.
    Hamdy FC; Donovan JL; Lane JA; Mason M; Metcalfe C; Holding P; Wade J; Noble S; Garfield K; Young G; Davis M; Peters TJ; Turner EL; Martin RM; Oxley J; Robinson M; Staffurth J; Walsh E; Blazeby J; Bryant R; Bollina P; Catto J; Doble A; Doherty A; Gillatt D; Gnanapragasam V; Hughes O; Kockelbergh R; Kynaston H; Paul A; Paez E; Powell P; Prescott S; Rosario D; Rowe E; Neal D
    Health Technol Assess; 2020 Aug; 24(37):1-176. PubMed ID: 32773013
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.